Cellectis (NASDAQ:CLLS) Share Price Passes Below 50-Day Moving Average – Time to Sell?

Cellectis S.A. (NASDAQ:CLLS) shares passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $3.37 and traded as low as $3.25. Cellectis shares last traded at $3.26, with a volume of 9,047 shares.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CLLS. Barclays raised their price target on Cellectis from $4.00 to $8.00 and gave the company an “overweight” rating in a report on Friday, October 17th. Wells Fargo & Company reaffirmed a “positive” rating and issued a $4.00 price target on shares of Cellectis in a report on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellectis in a report on Wednesday, October 8th. Finally, Wall Street Zen raised Cellectis to a “hold” rating in a report on Saturday, September 20th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $6.00.

Cellectis Price Performance

The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.38 and a current ratio of 1.38. The stock has a market capitalization of $181.19 million, a P/E ratio of -3.98 and a beta of 3.11. The firm has a 50-day moving average price of $3.37 and a 200 day moving average price of $2.39.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.09). The firm had revenue of $18.19 million for the quarter, compared to the consensus estimate of $10.07 million. Cellectis had a negative net margin of 100.69% and a negative return on equity of 68.05%. On average, analysts expect that Cellectis S.A. will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Cellectis

Several institutional investors have recently modified their holdings of the company. Acadian Asset Management LLC increased its position in shares of Cellectis by 132.9% during the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 26,461 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Cellectis by 228.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock valued at $5,856,000 after purchasing an additional 3,284,409 shares during the last quarter. Long Focus Capital Management LLC increased its position in shares of Cellectis by 2.2% during the 1st quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company’s stock valued at $5,849,000 after purchasing an additional 100,000 shares during the last quarter. Finally, OLD Mission Capital LLC bought a new position in shares of Cellectis during the 1st quarter valued at about $31,000. 63.90% of the stock is currently owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.